Company intelligence / Profile preview

TSI Group

Ownership: Public · TSI
Development stage: Commercial

Overview

TSI Group is an active global biotechnology organization specializing in research-driven nutritional ingredients and innovative solutions for consumer health. Their portfolio includes sustainable glucosamine production technology (GlucosaGreen®) and extensively studied muscle health ingredient MyHMB®. The company also provides advanced monitoring technologies to pharmaceutical manufacturers, medical device companies, healthcare facilities, ensuring product quality, compliance with regulatory standards, environmental safety, and optimized R&D processes. No clinical trial results as they do not develop drugs themselves.

Therapeutic areas: OtherMetabolic DisordersRheumatology
Modalities: Nutritional ingredientsSmall molecule (enabled)Biologic (enabled)
Industry: Food & Nutrition

Partnerships

Collaborates with brand partners globally to deliver finished goods or custom formulations

Beyond the preview

Go deeper on TSI Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSI Group.